De Brauw advises CureVac on its IPO and NASDAQ listing

De Brauw advised CureVac, a historically German clinical-stage biopharmaceutical company developing a new class of transformative medicines, on its IPO. As part of this process, CureVac was reorganized into a Dutch N.V., whose shares were listed on NASDAQ. CureVac is one of the leading European companies in the development of a vaccine for COVID-19.